ELVAF
Price
$0.90
Change
-$0.05 (-5.26%)
Updated
Nov 8 closing price
Capitalization
9.38M
GLABF
Price
$0.74
Change
-$0.03 (-3.90%)
Updated
May 21 closing price
Capitalization
54.89M
Interact to see
Advertisement

ELVAF vs GLABF

Header iconELVAF vs GLABF Comparison
Open Charts ELVAF vs GLABFBanner chart's image
Evolva Holding AG
Price$0.90
Change-$0.05 (-5.26%)
Volume$194
Capitalization9.38M
GEMINA LABORATORIES
Price$0.74
Change-$0.03 (-3.90%)
Volume$10.75K
Capitalization54.89M
ELVAF vs GLABF Comparison Chart
Loading...
View a ticker or compare two or three
VS
ELVAF vs. GLABF commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELVAF is a Hold and GLABF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (ELVAF: $0.90 vs. GLABF: $0.74)
Brand notoriety: ELVAF and GLABF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELVAF: 100% vs. GLABF: 78%
Market capitalization -- ELVAF: $9.38M vs. GLABF: $54.89M
ELVAF [@Biotechnology] is valued at $9.38M. GLABF’s [@Biotechnology] market capitalization is $54.89M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELVAF’s FA Score shows that 1 FA rating(s) are green whileGLABF’s FA Score has 1 green FA rating(s).

  • ELVAF’s FA Score: 1 green, 4 red.
  • GLABF’s FA Score: 1 green, 4 red.
According to our system of comparison, both ELVAF and GLABF are a bad buy in the long-term.

Price Growth

ELVAF (@Biotechnology) experienced а 0.00% price change this week, while GLABF (@Biotechnology) price change was +15.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.72%. For the same industry, the average monthly price growth was +2.76%, and the average quarterly price growth was -2.87%.

Industries' Descriptions

@Biotechnology (+0.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
GLABF($54.9M) has a higher market cap than ELVAF($9.38M). GLABF YTD gains are higher at: 35.482 vs. ELVAF (0.000). ELVAF has higher annual earnings (EBITDA): 1.05M vs. GLABF (-3.46M). ELVAF has more cash in the bank: 6.75M vs. GLABF (41.6K). ELVAF (0) and GLABF (0) have equivalent revenues.
ELVAFGLABFELVAF / GLABF
Capitalization9.38M54.9M17%
EBITDA1.05M-3.46M-30%
Gain YTD0.00035.482-
P/E RatioN/AN/A-
Revenue00-
Total Cash6.75M41.6K16,233%
Total DebtN/A1.46M-
FUNDAMENTALS RATINGS
ELVAF: Fundamental Ratings
ELVAF
OUTLOOK RATING
1..100
36
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
50
PRICE GROWTH RATING
1..100
73
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IJH59.76N/A
N/A
iShares Core S&P Mid-Cap ETF
TUR31.42N/A
N/A
iShares MSCI Turkey ETF
SCDL33.89N/A
N/A
ETRACS 2x Leveraged US Div Fctr TR ETN
GLOV53.43N/A
N/A
Goldman Sachs ActBt Wld Lw Vl Ps Eq ETF
QVAL43.97-0.09
-0.20%
Alpha Architect US Quantitative Val ETF

ELVAF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELVAF has been loosely correlated with REPL. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ELVAF jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELVAF
1D Price
Change %
ELVAF100%
N/A
REPL - ELVAF
60%
Loosely correlated
+3.55%
CLYYF - ELVAF
47%
Loosely correlated
N/A
IBIO - ELVAF
39%
Loosely correlated
N/A
GLABF - ELVAF
34%
Loosely correlated
N/A
NRSN - ELVAF
24%
Poorly correlated
-2.67%
More

GLABF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLABF has been loosely correlated with ELVAF. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if GLABF jumps, then ELVAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLABF
1D Price
Change %
GLABF100%
N/A
ELVAF - GLABF
36%
Loosely correlated
N/A
TNFA - GLABF
29%
Poorly correlated
N/A
IDRSF - GLABF
23%
Poorly correlated
N/A
VYGR - GLABF
22%
Poorly correlated
N/A
ENTO - GLABF
8%
Poorly correlated
+5.32%
More